AstraZeneca Results Presentation Deck
Full year and Q4 2021: performance
Oncology, CVRM, R&I and Rare Disease all delivered strong growth
Growth
across geographies (excluding Vaxzevria)
Q4 2021
$m
Oncology
CVRM
Respiratory &
Immunology
Rare Disease¹
Other medicines
Evusheld
Total revenue
excl. Vaxzevria
Vaxzevria²
Total Revenue
Growth
across disease areas
FY 2021
$m
13,663
8,034
6,049
3,071
2,484
135
33,436
3,981
37,417
CER
growth
%
17
9
(7)
n/m
23
n/m
38
Q4 2021
$m
3,919
2,007
1,593
1,760
835
135
10,250
1,762
12,011
CER
growth
%
21
8
3
11
14
n/m
39
n/m
63
US
EM
- EM excl. China
- China
Europe
Established
Rest of World
Total revenue
excl. Vaxzevria
Vaxzevria²
Total revenue
FY 2021
$m
12,164
9,977
3,977
6,000
7,015
4,280
33,436
3,981
37,417
CER
growth
%
38
10
21
22
21
23
n/m
38
Total revenue at actual exchange rates; changes at CER. R&I= Respiratory and Immunology; EM = emerging markets. 1. FY 2021 revenues from date of acquisition closing, 21 July 2021 through 31 December 2021; growth rates
7 calculated by comparison post-acquisition revenues with the corresponding prior year revenues adjusted pro-rata to match the post-acquisition. 2. Vaxzevria Total Revenue also includes Collaboration Revenue from sub-licensees
that produce and supply the AstraZeneca COVID-19 Vaccine under their own trademarks.
3,859
2,498
1,197
1,301
2,573
1,320
10,250
1,762
12,011
CER
growth
%
62
10
38
(9)
42
47
39
n/m
63View entire presentation